Function Health has secured US$450m in growth financing for its preventative healthcare testing and imaging platform.
US-based company said it has more than 500,000 members and has completed over 100m laboratory tests since launching its beta service in 2023.
The financing is non-dilutive, meaning Function can access the capital without issuing new shares or reducing the ownership stakes of existing shareholders.
It is linked to customer growth and is one of the largest deals of its type to date, following a similar US$200m commitment to healthcare AI company Commure in June 2025.
Founded in 2021, Function combines more than 160 laboratory tests with advanced imaging designed to identify early signs of cancer, aneurysms, stroke and hundreds of other conditions.
The company said its membership covers about five times as many tests as a standard annual physical and costs US$365 a year, equivalent to about US$1 a day.
Function was founded by Jonathan Swerdlin, Pranitha Patil, a Harvard Graduate School alumna, Dr Mark Hyman, Seth Weisfeld, Mike Nemke and Dan Swerdlin.
Swerdlin, co-founder and chief executive of Function, said: “Our mission is simple: enable you to live 100 healthy years.
“Everyone deserves to feel their best and avoid suffering. This growth financing allows us to bring that future of health into the present.”
The financing follows Function’s acquisitions of mobile laboratory service Getlabs and supplement information platform SuppCo. Financial terms for the deals were not disclosed.
Getlabs added nationwide blood collection at homes and workplaces, while SuppCo’s TrustScore system rates the reliability of over-the-counter supplements.
Function also acquired MRI scanning platform Ezra in May 2025, giving it access to a nationwide scanning network covering more than 200 locations.
Magnetic resonance imaging, or MRI, uses magnetic fields and radio waves to produce detailed images of structures inside the body without exposing patients to radiation.
